TetraLogic Pharmaceuticals Corp
OTC:TLOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
Xin Hwa Holdings Bhd
KLSE:XINHWA
|
MY |
|
Beijer Alma AB
STO:BEIA B
|
SE |
TetraLogic Pharmaceuticals Corp
Accrued Liabilities
TetraLogic Pharmaceuticals Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TetraLogic Pharmaceuticals Corp
OTC:TLOG
|
Accrued Liabilities
$3.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
TetraLogic Pharmaceuticals Corp
Glance View
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
See Also
What is TetraLogic Pharmaceuticals Corp's Accrued Liabilities?
Accrued Liabilities
3.2m
USD
Based on the financial report for Dec 31, 2015, TetraLogic Pharmaceuticals Corp's Accrued Liabilities amounts to 3.2m USD.
What is TetraLogic Pharmaceuticals Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
26%
Over the last year, the Accrued Liabilities growth was -15%. The average annual Accrued Liabilities growth rates for TetraLogic Pharmaceuticals Corp have been 26% over the past three years .
